EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access

Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler

Alexander S Rabin, Sarah M Seelye, Julien B Weinstein, Cainnear K Hogan, Taylor N Whittington, Jennifer Cano, Shelie A Miller, Catherine Kelley, Hallie C Prescott

JAMA Internal Medicine · 01.08.2025 · 185 (8) · 1005

DOI: 10.1001/jamainternmed.2025.2299 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.08.2025. Verfasst von Alexander S Rabin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Asthma, Bronchodilator Agents, Budesonide, Formoterol Fumarate Drug Combination, Fluticasone-Salmeterol Drug Combination. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Transitioning from metered-dose inhalers to propellant-free dry-powder inhalers could reduce health care–related greenhouse gas emissions, but the clinical difference in outcomes that may be associated with this switch is uncertain.

Objective

To evaluate the clinical difference in outcomes associated with a July 2021 Veterans Health Administration (VHA) formulary change that replaced budesonide-formoterol metered-dose inhaler with fluticasone-salmeterol dry-powder inhaler for the treatment of chronic obstructive pulmonary disease and asthma. Design, Setting, and Participants This within-person, self-controlled case series (SCCS) and matched observational cohort study (cohort study) used data from the US Veterans Affairs health care system from January 2018 through December 2022. Veterans who were prescribed a combination inhaler before and after the formulary change were included in both the SCCS and cohort study. Data were analyzed between April 19, 2024, and April 4, 2025. Exposures Treatment with budesonide-formoterol metered-dose inhaler vs fluticasone-salmeterol dry-powder inhaler. Main Outcomes and Measures Rescue medication use (albuterol and prednisone fills), emergency department visits, and hospitalizations (all-cause, respiratory-related, and pneumonia-specific) were assessed.

Results

Following the VHA formulary change, 260 268 patients switched from budesonide-formoterol metered-dose therapy to fluticasone-salmeterol dry-powder therapy. In the SCCS (median [IQR] age, 71 [62-75] years; 91% male), among patients who switched inhalers and experienced the adverse outcomes of interest, treatment with fluticasone-salmeterol dry-powder inhaler therapy was associated with a 10% decrease in albuterol fills (incidence rate ratio [IRR], 0.90 [95% CI, 0.90-0.91]), a 2% increase in prednisone fills (IRR, 1.02 [95% CI, 1.01-1.03]), a 5% increase in all-cause emergency department visits (IRR, 1.05 [95% CI, 1.04-1.06]), an 8% increase in all-cause hospitalizations (IRR, 1.08 [95% CI, 1.06-1.09]), a 10% increase in respiratory-related hospitalizations (IRR, 1.10 [95% CI, 1.07-1.14]), and a 24% increase in pneumonia-specific hospitalizations (IRR, 1.24 [95% CI, 1.17-1.31]). In the cohort study of 258 557 patients (mean [SD] age, 68.9 [11.3] years; 94% male), those who switched to a fluticasone-salmeterol dry-powder inhaler had no difference in mortality (1.89% vs 1.90%; adjusted absolute difference, −0.01 percentage points [95% CI, −0.12 to 0.10 percentage points]) but had increases in all-cause hospitalizations (16.14% vs 15.64%; adjusted absolute difference, 0.49 percentage points [95% CI, 0.21-0.78 percentage points]), respiratory-related hospitalizations (3.15% vs 2.74%; adjusted absolute difference, 0.41 percentage points [95% CI, 0.27-0.55 percentage points]), and pneumonia-related hospitalizations (1.15% vs 1.03%; adjusted absolute difference, 0.12 percentage points [95% CI, 0.04-0.21 percentage points]) at 180 days after the switch compared with matched patients who did not switch. Conclusions and Relevance The study found that the VHA formulary transition from budesonide-formoterol metered-dose inhaler to fluticasone-salmeterol dry-powder inhaler was associated with increased health care utilization, suggesting potential harm and the need to reevaluate this policy change.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBronchodilator AgentsBudesonide, Formoterol Fumarate Drug CombinationFluticasone-Salmeterol Drug CombinationPulmonary Disease, Chronic ObstructiveAgedFemaleHumansMaleMiddle AgedAdministration, InhalationDry Powder InhalersMetered Dose InhalersUnited States

Substanzen

Bronchodilator AgentsBudesonide, Formoterol Fumarate Drug CombinationFluticasone-Salmeterol Drug Combination

Autor:innen und Institutionen

  • Pulmonary Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Department of Internal Medicine, University of Michigan, Ann Arbor.
  • Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
  • School for Environment and Sustainability, University of Michigan, Ann Arbor.
  • Veterans Affairs Pharmacy Benefits Management Services, Hines, Illinois.

Förderung

  • HSRD VA

Zitieren

APA

Rabin, A. S., Seelye, S. M., Weinstein, J. B., Hogan, C. K., Whittington, T. N., Cano, J., Miller, S. A., Kelley, C., & Prescott, H. C. (2025). Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler. JAMA Internal Medicine, 185(8), 1005. https://doi.org/10.1001/jamainternmed.2025.2299

Vancouver

Rabin AS, Seelye SM, Weinstein JB, Hogan CK, Whittington TN, Cano J, et al. Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler. JAMA Internal Medicine. 2025;185(8):1005. doi:10.1001/jamainternmed.2025.2299

BibTeX
@article{Rabin2025,
  author = {Rabin, Alexander S and Seelye, Sarah M and Weinstein, Julien B and Hogan, Cainnear K and Whittington, Taylor N and Cano, Jennifer and Miller, Shelie A and Kelley, Catherine and Prescott, Hallie C},
  title = {Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler},
  journal = {JAMA Internal Medicine},
  year = {2025},
  volume = {185},
  number = {8},
  pages = {1005},
  doi = {10.1001/jamainternmed.2025.2299}
}
Kostenlos starten →